RecruitingNCT06854081

EluPro Antibiotic-Eluting BioEnvelope Registry

A Multi-Center Registry Evaluating EluPro Antibiotic-Eluting BioEnvelope During CIED Implantation


Sponsor

Elutia Inc.

Enrollment

100 participants

Start Date

Apr 17, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

A Multi-Center Registry Study Evaluating Participants Who Receive EluPro Antibiotic-Eluting BioEnvelope During CIED Implantation


Eligibility

Min Age: 18 Years

Inclusion Criteria4

  • Patient is undergoing implantation of EluPro with either a de novo CIED implantation or has an existing CIED and is undergoing CIED replacement or upgrade.
  • Patient is willing to comply with scheduled follow-up and study-related visits.
  • Patient is 18 years of age or older at the time of enrollment.
  • Patient agrees to provide written informed consent and use of PHI.

Exclusion Criteria9

  • Patient has a prior history of CIED infection, other prosthetic device infection, or endovascular infection, including endocarditis, in the past 12 months.
  • Patient is exhibiting signs or symptoms consistent with any type of active infection (including but not limited to pneumonia, urinary tract, cellulitis, or bacteremia).
  • Patient has Stage 4 or 5 kidney disease (eGFR <30 ml/min).
  • Patient requires long-term vascular access for any reason.
  • Patient is undergoing implantation of a CIED that does not fit completely into EluPro, preventing closure of the bioenvelope to secure the CIED.
  • Patient is currently on chronic immunosuppressive agents or ≥20mg/day of Prednisone or equivalent.
  • Patient has known allergy to minocycline or rifampin or their derivatives, or any other known contraindications to the implantation of EluPro.
  • Patient is participating in another clinical study that could impact the outcome and documented pre-approval from the study sponsor has not been obtained.
  • Female patient who is pregnant, or of childbearing potential and not on a reliable form of birth control. Women of childbearing potential are required to have a negative pregnancy test within 7 days prior to device procedure.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

COMBINATION_PRODUCTEluPro Antibiotic-Eluting BioEnvelope

Utilization of an EluPro Antibiotic-Eluting BioEnvelope with the CIED during the participant's CIED implant procedure.


Locations(4)

UC San Diego Health

La Jolla, California, United States

Tallahassee Research Institute

Tallahassee, Florida, United States

Brigham & Women's Hospital

Boston, Massachusetts, United States

Penn Presbyterian Medical Center

Philadelphia, Pennsylvania, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06854081


Related Trials